Switch theme
Sign up to access all valuation multiples
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
2004
127
LTM Revenue n/a
LTM EBITDA n/a
-$17.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Adlai Nortye has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Adlai Nortye achieved revenue of $5.0M and an EBITDA of -$101M.
Adlai Nortye expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Adlai Nortye valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $5.0M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$56.3M | -$101M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -2024% | XXX | XXX | XXX |
| Net Profit | -$56.7M | -$58.8M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -1176% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Adlai Nortye's stock price is $2.
Adlai Nortye has current market cap of $76.6M, and EV of -$17.0M.
See Adlai Nortye trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$17.0M | $76.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Adlai Nortye has market cap of $76.6M and EV of -$17.0M.
Adlai Nortye's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Adlai Nortye's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Adlai Nortye and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$17.0M | XXX | XXX | XXX |
| EV/Revenue | -3.4x | XXX | XXX | XXX |
| EV/EBITDA | 0.2x | XXX | XXX | XXX |
| P/E | -0.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAdlai Nortye's NTM/LTM revenue growth is n/a
Adlai Nortye's revenue per employee for the last fiscal year averaged $39K, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Adlai Nortye's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Adlai Nortye's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Adlai Nortye and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -2024% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 80% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $39K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 306% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1163% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1451% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adlai Nortye acquired XXX companies to date.
Last acquisition by Adlai Nortye was XXXXXXXX, XXXXX XXXXX XXXXXX . Adlai Nortye acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Adlai Nortye founded? | Adlai Nortye was founded in 2004. |
| Where is Adlai Nortye headquartered? | Adlai Nortye is headquartered in United States of America. |
| How many employees does Adlai Nortye have? | As of today, Adlai Nortye has 127 employees. |
| Who is the CEO of Adlai Nortye? | Adlai Nortye's CEO is Mr. Yang Lu. |
| Is Adlai Nortye publicy listed? | Yes, Adlai Nortye is a public company listed on NAS. |
| What is the stock symbol of Adlai Nortye? | Adlai Nortye trades under ANL ticker. |
| When did Adlai Nortye go public? | Adlai Nortye went public in 2023. |
| Who are competitors of Adlai Nortye? | Similar companies to Adlai Nortye include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Adlai Nortye? | Adlai Nortye's current market cap is $76.6M |
| Is Adlai Nortye profitable? | Yes, Adlai Nortye is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
